Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 125Neoplasm Metastasis 17Ovarian Neoplasms 12Endometrial Neoplasms 9Neoplasms 8Triple Negative Breast Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Uterine Cervical Neoplasms 5Prostatic Neoplasms 5Hereditary Sensory and Autonomic Neuropathies 5Colorectal Neoplasms 5Advanced Breast Cancer 5Squamous Cell Carcinoma of Head and Neck 4Stomach Neoplasms 3Recurrence 3Neoplasms by Site 3Head and Neck Neoplasms 3Carcinoma, Lobular 3Breast Diseases 3Breast Cancer Metastatic 3Uterine Neoplasms 2Small Cell Lung Carcinoma 2Multiple Endocrine Neoplasia Type 1 2Melanoma 2Locally Advanced (Inoperable) or Metastatic Breast Cancer 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Advanced Solid Tumors 2Urologic Neoplasms 1Urogenital Neoplasms 1

Interventions

trifluridine tipiracil drug combination 1pembrolizumab 1Trifluridine 1Standard of Care 1Injections 1HMPL-013 1Fulvestrant 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced/Metastatic Solid Tumors × Fulvestrant × 1 year × Clear all
NCT07480681 2026-03-18

Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor

Shanghai Henlius Biotech

Phase 1 Not yet recruiting
138 enrolled
Other solid neoplasm

Advanced/Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡